InVivo Therapeutics Announces Stanford Medicine as New Site for INSPIRE Study
July 12 2017 - 8:00AM
Business Wire
InVivo Therapeutics Holdings Corp. (NVIV) today
announced that Stanford Medicine in Stanford, CA has been added as
a clinical site for The INSPIRE Study: InVivo Study
of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety
and Neurologic Recovery in Subjects with Complete Thoracic
AIS A Spinal Cord Injury. Atman Desai, MD, has been named Principal
Investigator at the site. Dr. Desai is a Director of Neurosurgical
Spinal Oncology and Clinical Assistant Professor of Neurosurgery at
Stanford University Medical Center.
Mark Perrin, InVivo’s CEO and Chairman, said, “We are pleased to
welcome one of the most recognized hospitals in the world to the
INSPIRE Study. We look forward to working with Stanford Medicine
and Dr. Desai, especially given Dr. Desai’s expertise in spinal
cord injury treatment.”
There are now 34 clinical sites participating in the clinical
study:
- Allegheny General Hospital, Pittsburgh,
PA
- Banner University Medical Center,
Tucson, AZ
- Barnes-Jewish Hospital at Washington
University Medical Center, St. Louis, MO
- Barrow Neurological Institute – St.
Joseph’s Hospital and Medical Center, Phoenix, AZ
- Ben Taub Hospital/Baylor College of
Medicine, Houston, TX
- Beth Israel Deaconess Medical Center,
Boston, MA
- Brigham and Women’s Hospital, Boston,
MA
- Carolina Neurosurgery and Spine
Associates/Carolinas Rehabilitation, Charlotte, NC
- Cooper Neurological Institute, Camden,
NJ
- Foothills Medical Centre, Calgary,
Alberta, Canada
- Goodman Campbell Brain and
Spine/Indiana University Health Neuroscience Center, Indianapolis,
IN
- Hospital of the University of
Pennsylvania, Philadelphia, PA
- James Cook University Hospital,
Middlesbrough, United Kingdom
- Keck Hospital of University of Southern
California, Los Angeles, CA
- Medical College of Wisconsin/Froedtert
Hospital, Milwaukee, WI
- Mount Sinai Hospital, New York, NY
- Northwestern Medicine, Chicago, IL
- Oregon Health & Science University,
Portland, OR
- Rhode Island Hospital, Providence,
RI
- Rutgers New Jersey Medical School,
Newark, NJ
- Stanford Medicine, Stanford,
CA
- St. Michael’s Hospital, Toronto,
Ontario, Canada
- Thomas Jefferson University Hospital,
Philadelphia, PA
- Toronto Western Hospital, Toronto,
Ontario, Canada
- University of California, Davis Medical
Center, Sacramento, CA
- University of California, San Diego
Medical Center, San Diego, CA
- University of Iowa Hospitals and
Clinics, Iowa City, IA
- University of Kansas Medical Center,
Kansas City, KS
- University of Louisville Hospital,
Louisville, KY
- University of New Mexico Hospital,
Albuquerque, NM
- University of Pittsburgh Medical Center
Presbyterian, Pittsburgh, PA
- University of Virginia Health System,
Charlottesville, VA
- Vidant Medical Center, Greenville,
NC
For more information, please visit the company’s
ClinicalTrials.gov registration site:
http://clinicaltrials.gov/ct2/show/study/NCT02138110.
About the Neuro-Spinal Scaffold™ ImplantFollowing acute
spinal cord injury, surgical implantation of the biodegradable
Neuro-Spinal Scaffold within the decompressed and debrided injury
epicenter is intended to support appositional healing, thereby
reducing post-traumatic cavity formation, sparing white matter, and
allowing neural repair within and around the healed wound
epicenter. The Neuro-Spinal Scaffold, an investigational device,
has received a Humanitarian Use Device (HUD) designation and
currently is being evaluated in The INSPIRE Study for the treatment
of patients with acute, complete (AIS A), thoracic traumatic spinal
cord injury and a pilot study for acute, complete (AIS A), cervical
(C5-T1) traumatic spinal cord injury. For more information on the
cervical study, refer to
https://clinicaltrials.gov/ct2/show/study/NCT03105882.
About InVivo TherapeuticsInVivo Therapeutics Holdings
Corp. is a research and clinical-stage biomaterials and
biotechnology company with a focus on treatment of spinal cord
injuries. The company was founded in 2005 with proprietary
technology co-invented by Robert Langer, Sc.D., Professor at
Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D.,
who then was at Boston Children’s Hospital and who now is
affiliated with Massachusetts General Hospital. In 2011, the
company earned the David S. Apple Award from the American Spinal
Injury Association for its outstanding contribution to spinal cord
injury medicine. In 2015, the company’s investigational
Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine
Device Award. The publicly-traded company is headquartered in
Cambridge, MA. For more details, visit
www.invivotherapeutics.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170712005395/en/
InVivo TherapeuticsHeather Hamel, 617-863-5530Investor
RelationsInvestor-relations@invivotherapeutics.com
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Apr 2024 to May 2024
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From May 2023 to May 2024